A Real-World Efficacy and Safety of KEYNOTE-522 Regimen in Patients With Early Triple-Negative Breast Cancer
Authors:
- Shinyoung LeeSLShinyoung Lee
- Hyehyun JeongHJHyehyun Jeong
- Yeokyeong ShinYSYeokyeong Shin
- Jae Ho JeongJJJae Ho Jeong
- Kyung Hae JungKJKyung Hae Jung
- Sung-Bae KimSKSung-Bae Kim
- Byung-Kwan JeongBJByung-Kwan Jeong
- Hee Jin LeeHLHee Jin Lee
- Gyungyub GongGGGyungyub Gong
- Hee Jung ShinHSHee Jung Shin
- Hye Joung EomHEHye Joung Eom
- Young-Jin LeeYLYoung-Jin Lee
Open Access
- 1 January 2026
- journal article
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (2) , 141-153
Abstract
Lee S, et al. J Breast Cancer. 2026 ;29:e9. https://doi.org/10.4048/jbc.2025.0256Keywords
Funding Information
- Asan Institute for Life Sciences, Asan Medical Center (2025IP0054)
This publication has 32 references indexed in Scilit:
- Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerJAMA, 2024
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522Annals of Oncology, 2024
- Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast CancerJAMA Oncology, 2024
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysisAnnals of Oncology, 2023
- Low axillary sampling to stage post neoadjuvant axilla in breast cancer patients - A practical approach in developing worldClinical Surgical Oncology, 2023
- Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast CancerJAMA Network Open, 2023
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer SubtypesJAMA Oncology, 2016
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012